FDA approves an easy-to-use glucagon rescue pen for severe hypoglycemia in diabetes
The US Food and Drug Administration (FDA) has approved a prefilled glucagon rescue pen (Gvoke HypoPen, Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in adult and pediatric patients aged 2 years or older who have diabetes. Gvoke will be available in two doses: a 0.5-mg/0.1 mL dose for pediatric patients, and a 1-mg/0.2 mL dose for adolescent and adult patients… (Medscape)
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies